BioLineRx Ltd. (TLV:BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 2.100
+0.100 (4.76%)
Aug 14, 2025, 5:24 PM IDT
BioLineRx Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -7.82 | -9.22 | -60.61 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Depreciation & Amortization | 3.99 | 3.99 | 1.33 | 0.65 | 0.7 | 0.93 | Upgrade
|
| Other Amortization | 0.74 | 0.74 | 0.06 | 0.17 | - | 0.59 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.26 | 1.26 | 6.7 | - | - | - | Upgrade
|
| Stock-Based Compensation | 1.14 | 1.14 | 2.32 | 2.25 | 1.5 | 1.27 | Upgrade
|
| Other Operating Activities | 1.31 | -19.96 | 12.4 | -5.6 | 1.82 | 5.3 | Upgrade
|
| Change in Accounts Receivable | -2.12 | -2.12 | -0.36 | - | - | - | Upgrade
|
| Change in Inventory | -1.19 | -1.19 | -1.95 | - | - | - | Upgrade
|
| Change in Accounts Payable | -5.51 | -5.51 | 5.51 | 1.89 | -0.56 | -1.72 | Upgrade
|
| Change in Unearned Revenue | -12.96 | -12.96 | 12.96 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -0.04 | -0.04 | -0.96 | -0.65 | 0.02 | 0.43 | Upgrade
|
| Operating Cash Flow | -21.2 | -43.87 | -22.61 | -26.24 | -23.57 | -23.21 | Upgrade
|
| Capital Expenditures | 0.02 | -0.05 | -0.12 | -0.13 | -0.1 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0 | -0 | -0.18 | -0.19 | - | - | Upgrade
|
| Investment in Securities | 9.44 | 29.43 | 1.74 | 4.32 | -38.13 | 16.67 | Upgrade
|
| Investing Cash Flow | 9.45 | 29.37 | 1.44 | 4.01 | -38.22 | 16.67 | Upgrade
|
| Long-Term Debt Issued | - | 19.22 | - | 9.13 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -14.94 | -1.99 | -3.05 | -3.57 | -3.36 | Upgrade
|
| Net Debt Issued (Repaid) | -15.64 | 4.28 | -1.99 | 6.07 | -3.57 | -3.36 | Upgrade
|
| Issuance of Common Stock | 24.37 | 16.38 | 17.04 | 14.36 | 61.32 | 21.22 | Upgrade
|
| Financing Cash Flow | 8.73 | 20.66 | 15.06 | 20.44 | 57.75 | 17.87 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.59 | 0.02 | -0.22 | -0.61 | 0.21 | 0.21 | Upgrade
|
| Net Cash Flow | -2.43 | 6.18 | -6.33 | -2.4 | -3.84 | 11.53 | Upgrade
|
| Free Cash Flow | -21.19 | -43.93 | -22.72 | -26.37 | -23.67 | -23.21 | Upgrade
|
| Free Cash Flow Margin | -122.81% | -151.78% | -473.42% | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.04 | -0.02 | -0.03 | -0.04 | -0.09 | Upgrade
|
| Cash Interest Paid | 10.39 | 10.39 | 1.11 | 0.59 | 0.68 | 0.99 | Upgrade
|
| Levered Free Cash Flow | -10.04 | -43.89 | 2.33 | -15.32 | -14.54 | -13.66 | Upgrade
|
| Unlevered Free Cash Flow | -5.82 | -38.21 | 3.67 | -14.2 | -13.92 | -12.74 | Upgrade
|
| Change in Working Capital | -21.82 | -21.82 | 15.2 | 1.24 | -0.54 | -1.29 | Upgrade
|
Updated Nov 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.